Author:
Mauskopf Josephine,Earnshaw Stephanie
Publisher
Springer International Publishing
Reference10 articles.
1. Asche CV, Clay E, Kharitonova E, Zah V, Ruby J, Aballea S. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States. J Med Econ. 2015;18(8):600–11.
2. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104(6):982–92. doi: 10.1111/j.1360-0443.2009.02539.x . Cited in: Asche et al., 2015
3. Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(Suppl 8):S235–48. Cited in: Asche et al., 2015
4. Bonita R, Solomon N, Broad JB. Prevalence of stroke and stroke-related disability. Estimates from the Auckland Stroke Studies. Stroke. 1997;28(10):1898–902. Cited in: Mar et al., 2010.
5. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Value Health. 2012;15(6):843–50.